Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 9/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.61 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.52 |
| ▸ | C5AR1 | P21730 | 3/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | HTR3A | P46098 | 1/20 | 0.46 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.46 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.45 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | HPD | P32754 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2604460 | 0.85 | OPRL1 (0.61) | OPRL1OPRM1OPRK1OPRD1C5AR1 | |
| SCHEMBL1858426 | 0.84 | OPRL1 (0.60) | OPRL1OPRM1OPRK1OPRD1C5AR1 | |
| SCHEMBL8060424 | 0.84 | OPRL1 (0.60) | OPRL1OPRM1OPRK1OPRD1C5AR1 | |
| SCHEMBL1863057 | 0.79 | OPRL1 (0.61) | OPRL1OPRM1OPRK1OPRD1TMEM97 | |
| SCHEMBL1861485 | 0.79 | OPRL1 (0.52) | OPRL1OPRM1OPRK1OPRD1C5AR1 | |
| SCHEMBL2604457 | 0.79 | OPRL1 (0.52) | OPRL1OPRM1OPRK1OPRD1C5AR1 | |
| SCHEMBL2604458 | 0.78 | OPRL1 (0.54) | OPRL1OPRM1OPRK1OPRD1C5AR1 | |
| SCHEMBL25407563 | 0.78 | ALDH1A1 (0.65) | OPRL1OPRM1OPRK1OPRD1SLC6A4 | |
| SCHEMBL1861042 | 0.77 | OPRL1 (0.65) | OPRL1OPRM1OPRK1OPRD1TMEM97 | |
| SCHEMBL20845727 | 0.76 | OPRL1 (0.52) | OPRL1OPRM1OPRK1OPRD1C5AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252815-B2 | Nociceptin analogs | PURDUE PHARMA L.P. (US) | 2012-08-28 | — | — | US | disclosed |
| US-8252815-B2 | Nociceptin analogs | PURDUE PHARMA L.P. (US) | 2012-08-28 | — | — | US | disclosed |
| US-20120095049-A1 | NOCICEPTIN ANALOGS | PURDUE PHARMA L.P. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095049-A1 | NOCICEPTIN ANALOGS | PURDUE PHARMA L.P. (US) | 2012-04-19 | — | — | US | disclosed |
| US-7939670-B2 | Nociceptin analogs | PURDUE PHARMA L.P. (US) | 2011-05-10 | — | — | US | disclosed |
| US-7939670-B2 | Nociceptin analogs | PURDUE PHARMA L.P. (US) | 2011-05-10 | — | — | US | disclosed |
| US-20090156640-A1 | NOCICEPTIN ANALOGS | EURO-CELTIQUE S.A. | 2009-06-18 | — | — | US | disclosed |
| US-20090156640-A1 | NOCICEPTIN ANALOGS | EURO-CELTIQUE S.A. | 2009-06-18 | — | — | US | disclosed |
| US-7495109-B2 | Nociceptin analogs | PURDUE PHARMA L.P. (US) | 2009-02-24 | — | — | US | disclosed |
| US-7495109-B2 | Nociceptin analogs | PURDUE PHARMA L.P. (US) | 2009-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156640-A1 | NOCICEPTIN ANALOGS | OPRL1, NPY1R, NPBWR1 | OPRL1 1/4885OPRM1 8/4885OPRK1 5/4885 |
| US-20120095049-A1 | NOCICEPTIN ANALOGS | OPRL1, NPY1R, NPBWR1 | OPRL1 1/4885OPRM1 8/4885OPRK1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.